, Jan. 7, 2020
/PRNewswire-PRWeb/ -- Predicine, a molecular insights company headquartered in Hayward, California
, with global footprints in China
, today announced results from a collaborative biomarker study with Merck KGaA, Darmstadt, Germany
, a leading science and technology company operating its biopharmaceuticals business in the U.S. and Canada
as EMD Serono, will be jointly presented at the American Association for Cancer Research (AACR) - Advances in Liquid Biopsies Conference, taking place from January 13 to 16, 2020
in Miami, Florida
. The study explores the potential clinical utility of Predicine's proprietary liquid biopsy platforms for detection of genetic alterations using plasma-derived circulated tumor DNA (ctDNA) and cell-free RNA (cfRNA) in patients with advanced colorectal cancer (CRC).
Highlights of this study include:
- The clinical feasibility of simultaneous multiparametric profiling using a combined cfDNA and cfRNA liquid biopsy approach for molecular characterization in advanced CRC.
- cfRNA-derived variant detection confirms the variants originally detected in cfDNA test and validates the high specificity results for report interpretation.
- cfDNA-based detection of tumor mutation burden (TMB).
Data to be presented also support the role of clinical implementation of a combined cfDNA and cfRNA test that could provide holistic molecular insight for detecting cancer driver mutations, monitoring efficacy/disease burden, as well as identifying sub-clonal alterations that may be relevant to drug resistance and tumor heterogeneity.
"We are very delighted to work with Merck KGaA, Darmstadt, Germany
, a precision medicine driven company. We have a shared vision of the critical role of liquid biopsy in revolutionizing personalized cancer treatments and clinical drug development," said Dr. Shidong Jia
, Founder and CEO at Predicine. "Predicine's next-generation sequencing-based comprehensive non-invasive liquid biopsy platform adds value by enabling biomarker-driven patient selection & enrollment, longitudinal disease monitoring and exploring the new paradigm for both targeted and combination therapies."
Predicine is a molecular insights company that is committed to advancing biomarker-driven precision medicine. Predicine has developed a breakthrough RNA- and DNA-based liquid biopsy technology for non-invasive cancer profiling, disease monitoring and assessing minimal residual disease. Through its CLIA and/or CAP facilities in the US and China
, Predicine partners with leading biopharma companies and hospitals to support global clinical trials and personalized cancer therapy.